AI biological clocks indicate popular weight loss medications may slow human aging

Pharmaceutical companies Novo Nordisk and Eli Lilly presented research showing that widely used obesity treatments might slow human aging. Researchers used machine learning models trained on blood datasets to calculate cellular age across thousands of clinical trial participants. As reported by MIT Technology Review, patients taking GLP-1 therapies measured two to three years younger biologically than those receiving a placebo, with certain heart markers indicating even larger drops.

The findings offer strong evidence that these medications act on deep biological mechanisms of aging rather than just assisting with weight control. For the average person, this could mean future medical care focused on extending healthy lifespan rather than just managing individual diseases. However, scientists noted that while the anti-aging effect is visible in patients dealing with metabolic conditions, there is no proof yet that healthy individuals would see the same results.

This development also validates the use of computational biological clocks as legitimate tools for evaluating medical treatments in large trials. Still, it remains unclear whether these cellular changes actually translate into extra years of healthy life or simply reflect improved metabolic metrics. Furthermore, if these drugs are eventually repurposed for longevity, healthcare systems will face massive challenges determining who should receive coverage for preventative aging care.